Table 1.

Actions, roles, and responsibilities as discussed in the expert meeting.

Themes	Actions	Responsible stakeholder(s)
Division of responsibilities	*Develop a national guideline on collaboration.	Health care provider organizations of pharmacists and GPs (KNMP/NHG).
	Make agreements on a regional level about when and who can request PGx tests.	Regional groups for pharmacotherapeutic consultation (local organization of GPs and pharmacists).
Data registration and sharing	*Define relevant data that should be registered and shared between health care professionals for effective use of PGx.	Health care provider organizations of pharmacists and GPs (KNMP/NHG).
	*Standardize patient data that needs to be registered with regard to PGx.	Health care provider organizations of pharmacists and GPs (KNMP/NHG) and NICTIZ (National IT Institute in Health Care).
	Further develop the National Link Point to enable easy exchange of PGx data between health care professionals.	VZVZ (Association of health care providers for health communication) at the initiative of the health care provider organizations (KNMP/NHG) in collaboration with NICTIZ (National IT Institute in Health Care).
	Facilitate aligned registration for the reason of adjusting a patient’s treatment regime, to monitor and evaluate effectiveness of applying PGx.	NICTIZ (National IT Institute in Health Care), in collaboration with software developers HIS/AIS (information systems for GPs/pharmacists), at the initiative of the Dutch GP association (LHV)/Royal Dutch Pharmacists Association (KNMP).
	Adjust or develop software systems to facilitate applying PGx.	Software developers HIS/AIS (information systems for GPs/pharmacists), at the initiative of the Dutch GP association (LHV)/Royal Dutch Pharmacists Association (KNMP), in collaboration with NICTIZ (National IT Institute in Health Care).
Generating evidence for guideline development	*Gather data on the number of prevented ineffective or adverse drug responses through PGx.	Funders for research/independent research institutes/scientific organizations.
	*Validate the predictive value of PGx tests through prospective or observational research.	Scientific organizations.
	*Assess the cost saving of PGx test through pharmaco-economic studies.	Scientific organizations.
	*Collect data on the impact on clinical outcomes by assessing the patient experience of the severity of ineffective or adverse drug response.	Scientific organizations, together with patient organizations.
	*Develop aligned patient information on the benefit of PGx tests. Monitor data on the frequency of genetic variants that are tested with PGx.	Health care provider organizations (KNMP/NHG) of pharmacists and GPs together with patient organizations Independent research institutes.
	Monitor data on the frequency of genetic variants that are tested with PGx.	Independent research institutes.
Reimbursement	*Include PGx tests as an optional test for general practitioners in their guideline.	Dutch organization for general practitioners (NHG).
	Develop aligned patient information on the costs of PGx test and the impact on their health care insurance reimbursement.	Health care provider organizations of pharmacists and GPs (KNMP/NHG), in collaboration with ZN (Dutch Health Care Insurers) and patient organizations.
	Define and prioritize disease areas eligible for reimbursement based on data on clinical utility.	Health insurers and ZINl (Dutch Health Care Institute).

Statements preceded by an asterisk (*) remained after three iterations of the Delphi procedure. PGx pharmacogenetics, GP general practitioner.